日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications

依库珠单抗和拉武珠单抗治疗脑膜炎球菌感染的临床试验及真实世界药物警戒

Carrillo Infante, Cynthia; Mujeebuddin, Arshad

GC-MS/MS analysis of synthetic cannabinoids 5F-MDMB-PICA and 5F-CUMYL-PICA in forensic cases

法医案件中合成大麻素 5F-MDMB-PICA 和 5F-CUMYL-PICA 的 GC-MS/MS 分析

Hatem Ahmed ,Syed Mujeebuddin

A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement

一项针对伴有下消化道受累的急性移植物抗宿主病(GVHD)的C5a补体抑制剂的前瞻性II期临床试验

Mehta, Rohtesh S; Ali, Haris; Dai, Yang; Yao, Bert; Overman, Bethany; Ratanatharathorn, Voravit; Gill, Saar; Socié, Gerard; Anderson, Kevin; Cahn, Jean Yves; Mujeebuddin, Arshad; Champlin, Richard; Shpall, Elizabeth; Holtan, Shernan G; Alousi, Amin

Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies

拉武利珠单抗治疗阵发性睡眠性血红蛋白尿症患者的长期安全性和有效性:两项关键性3期研究的2年结果

Kulasekararaj, Austin G; Griffin, Morag; Langemeijer, Saskia; Usuki, Kensuke; Kulagin, Alexander; Ogawa, Masayo; Yu, Ji; Mujeebuddin, Arshad; Nishimura, Jun-Ichi; Lee, Jong Wook; Peffault de Latour, Régis

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis

依库珠单抗治疗阵发性睡眠性血红蛋白尿和非典型溶血性尿毒综合征:10 年药物警戒分析

Socié, Gérard; Caby-Tosi, Marie-Pierre; Marantz, Jing L; Cole, Alexander; Bedrosian, Camille L; Gasteyger, Christoph; Mujeebuddin, Arshad; Hillmen, Peter; Vande Walle, Johan; Haller, Hermann

Study of Middle Cerebral Artery in Human Cadaveric Brain

对人类尸体脑中脑动脉的研究

Gunnal, Sandhya Arvind; Farooqui, Mujeebuddin Samsamuddin; Wabale, Rajendra Namdeo

Loratadine versus levocetirizine in chronic idiopathic urticaria: A comparative study of efficacy and safety

氯雷他定与左西替利嗪治疗慢性特发性荨麻疹:疗效和安全性比较研究

Anuradha, P; Maiti, Rituparna; Jyothirmai, J; Mujeebuddin, Omer; Anuradha, M